The earnings call highlighted significant revenue growth and promising clinical trial results, particularly for BRTX-100, alongside a strong financial position with no debt. However, these positives were tempered by an increased operational loss and uncertainty in future revenue projections from the BioCosmeceutical business. On balance, the achievements and progress in clinical trials and regulatory pathways suggest a positive outlook.

Company Guidance -

Q3 2025

During the BioRestorative Therapies second quarter 2025 conference call, the company reported a significant 240% increase in revenue to $303,000, mainly driven by their contract manufacturing agreement in BioCosmeceuticals. Despite a loss from operations of $3.3 million, the net loss decreased to $2.7 million from $4 million in the prior year. Financially, the company ended the quarter with $7.4 million in cash and no outstanding debt. The ongoing Phase II trial of their lead candidate, BRTX-100, showed promising results, with over 74% of subjects experiencing greater than 50% improvement in function and over 72% reporting over 50% pain reduction by 52 weeks. Additionally, the company is advancing discussions with the FDA for a potential Type B meeting to expedite regulatory approval. BioRestorative is also exploring licensing opportunities for its ThermoStem metabolic disease programs and expanding its BioCosmeceutical platform.

Significant Revenue Growth

Second quarter 2025 revenues were $303,000, representing an increase of 240% compared to $89,000 in the same period last year, primarily due to a contract manufacturing agreement on BioCosmeceuticals.

Improved Financial Position

The company ended the quarter with cash, cash equivalents, and marketable securities of $7.4 million and no outstanding debt.

Promising Clinical Trial Results

In the ongoing Phase II trial of BRTX-100, over 74% of subjects showed greater than 50% improvement in function, and over 72% reported greater than 50% reduction in pain by 52 weeks. No serious adverse events were reported.

Regulatory Progress and Enrollment

The company is more than halfway through enrollment for their 99-subject goal for the BRTX-100 trial and plans to meet with the FDA to accelerate the regulatory pathway.

BioRestorative Therapies (BRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.36 / -	-0.13	―	―	―
Aug 12, 2025	2025 (Q2)	-0.37 / -0.30	-0.5	40.00% (+0.20)	―
May 14, 2025	2025 (Q1)	-0.33 / -0.64	-0.33	-93.94% (-0.31)	―
Mar 27, 2025	2024 (Q4)	-0.34 / -0.20	-0.6	66.67% (+0.40)	―
Nov 12, 2024	2024 (Q3)	-0.43 / -0.13	-0.64	79.69% (+0.51)	―
Aug 13, 2024	2024 (Q2)	-0.57 / -0.50	-0.77	35.06% (+0.27)	―	―
May 14, 2024	2024 (Q1)	-0.52 / -0.33	-1.53	78.43% (+1.20)	―	―
May 15, 2018	2018 (Q1)	- / -1560.00	-2240	30.36% (+680.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$1.47	$1.50	+2.04%
May 14, 2025	$1.71	$1.67	-2.34%
Mar 27, 2025	$1.83	$1.81	-1.09%
Nov 12, 2024	$1.64	$1.54	-6.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioRestorative Therapies (BRTX) report earnings?

BioRestorative Therapies (BRTX) is schdueled to report earning on Nov 18, 2025, After Close (Confirmed).

What is BioRestorative Therapies (BRTX) earnings time?

BioRestorative Therapies (BRTX) earnings time is at Nov 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BRTX EPS forecast?

BRTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.36.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing